Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study will determine the overall response rate and toxicity of rituximab and Velcade in
combination in patients with relapsed or refractory mantle cell non-Hodgkin's lymphoma.